Matrixyl (Palmitoyl Pentapeptide-4)

1. Overview

Matrixyl is the trade name for palmitoyl pentapeptide-4 (Pal-KTTKS), a synthetic lipopeptide consisting of the pentapeptide sequence lysine-threonine-threonine-lysine-serine (KTTKS) conjugated to palmitic acid, a 16-carbon saturated fatty acid. The peptide was developed by Sederma SAS (now part of Croda International) and launched in 2000 as the first peptide active ingredient specifically designed for anti-aging cosmetic applications [3][9].

The KTTKS sequence was originally identified in 1993 by Katayama et al. at the University of Tennessee as a subfragment of the C-terminal propeptide of type I procollagen (spanning residues 197-241 of the propeptide domain) [1]. Among the various subfragments tested, KTTKS was determined to be the minimum sequence capable of retaining approximately 80% of the parent fragment's activity in stimulating extracellular matrix production by human dermal fibroblasts [1]. The palmitoyl modification was subsequently introduced by Lintner and colleagues at Sederma to overcome the poor skin permeation of the unmodified hydrophilic pentapeptide, improving cutaneous penetration by a factor of 100 to 1000 [3].

Matrixyl belongs to the class of signal peptides known as matrikines -- messenger peptides derived from extracellular matrix proteins that regulate cell activity by interacting with specific receptors [2][4]. The matrikine concept, formalized by Maquart et al. in 1999, describes how peptide fragments generated during ECM degradation serve as biological signals to surrounding cells, creating a feedback loop that regulates connective tissue remodeling [2].

The complete palmitoyl pentapeptide-4 molecule has a molecular weight of approximately 802 g/mol and the molecular formula C39H75N7O10 [10]. It is commercially supplied as Matrixyl in a glycerin-water vehicle and is incorporated into cosmetic formulations at concentrations typically ranging from 3 to 5 ppm of the active peptide [5][9].

Matrixyl received the Sederma 25 Years of Innovation Award, recognizing it as the product with the greatest impact on the personal care ingredients market. Over 1500 commercial skincare products worldwide contain Matrixyl in their formulations [9].

Molecular Weight

~802.05 g/mol (Pal-KTTKS)

Sequence

Pal-Lys-Thr-Thr-Lys-Ser (palmitic acid + KTTKS)

CAS Number

214047-00-4

Parent Sequence

KTTKS from procollagen I C-terminal propeptide (residues 197-241)

Trade Name

Matrixyl (Sederma / Croda International)

Routes Studied

Topical (cream/serum/patch)

FDA Status

Not regulated as drug; marketed as cosmetic ingredient (INCI: Palmitoyl Pentapeptide-4)

WADA Status

Not specifically listed

2. Mechanism of Action

Matrixyl exerts its biological effects through a matrikine signaling mechanism, functioning as a synthetic analog of the peptide fragments naturally released during collagen degradation. By mimicking these degradation products, Pal-KTTKS triggers a compensatory biosynthetic response in dermal fibroblasts [1][2][4].

Matrikine Signaling and Collagen Feedback Loop

The KTTKS sequence functions as a fragment of the procollagen I C-terminal propeptide, which is cleaved during the conversion of procollagen to mature collagen [1]. When fibroblasts detect elevated levels of these propeptide fragments -- whether from natural collagen turnover or from exogenously applied Pal-KTTKS -- they interpret this as a signal that collagen degradation has occurred and respond by upregulating synthesis of new extracellular matrix components [1][4][8].

In vitro studies have demonstrated that KTTKS stimulates fibroblast production of multiple ECM components in a dose- and time-dependent manner [1]:

• Collagen type I -- the primary structural protein of the dermis, constituting approximately 80% of dermal collagen
• Collagen type III -- a fibrillar collagen important for skin elasticity and wound repair
• Collagen type IV -- the principal component of the basement membrane at the dermal-epidermal junction
• Fibronectin -- a glycoprotein essential for cell adhesion, migration, and ECM organization
• Glycosaminoglycans -- polysaccharides including hyaluronic acid that maintain dermal hydration and volume

Importantly, this stimulatory effect was shown to be specific to ECM components, with no effect on total protein synthesis or the ratio of secreted to cell-associated proteins, indicating a targeted signaling mechanism rather than a generalized increase in cellular biosynthetic activity [1].

TGF-beta Pathway Involvement

Tsai et al. (2007) provided mechanistic evidence linking KTTKS activity to the transforming growth factor-beta (TGF-beta) signaling pathway [6]. In tendon cell cultures treated with KTTKS:

• The concentration of TGF-beta in conditioned medium increased in a dose-dependent manner
• mRNA expression of alpha-1(I) procollagen was significantly upregulated
• The mRNA-stabilizing protein mRBP K was enhanced, slowing degradation of procollagen mRNA
• KTTKS maintained procollagen mRNA stability, effectively prolonging the biosynthetic signal [6]

TGF-beta is a master regulator of ECM production in fibroblasts, known to cause sustained increases in steady-state levels of type I and type III collagen mRNAs (2-3 fold) and fibronectin mRNAs (5-8 fold) in normal human dermal fibroblasts. The upregulation of TGF-beta by KTTKS therefore provides a plausible mechanism for the peptide's broad stimulatory effect on multiple ECM components [6].

Collagenase Inhibition

In addition to stimulating new matrix synthesis, Pal-KTTKS has been reported to inhibit collagenase (matrix metalloproteinase) activity, thereby reducing the enzymatic degradation of existing collagen fibers [8][9]. This dual mechanism -- promoting synthesis while limiting degradation -- may contribute to a net increase in dermal collagen content.

Enhanced Skin Penetration via Palmitoylation

The palmitoyl (C16 fatty acid) chain conjugated to the N-terminus of KTTKS serves a critical delivery function. The unmodified KTTKS pentapeptide is highly hydrophilic and has minimal capacity to penetrate the lipid-rich stratum corneum barrier [3][10].

Choi et al. (2014) demonstrated this difference using Franz diffusion cell experiments with hairless mouse skin [10]:

• KTTKS alone: not detected in any skin layer (stratum corneum, epidermis, or dermis)
• Pal-KTTKS: detected in all layers -- 4.2 micrograms per square centimeter in stratum corneum, 2.8 micrograms per square centimeter in epidermis, and 0.3 micrograms per square centimeter in dermis

Furthermore, Pal-KTTKS demonstrated superior stability against proteolytic degradation compared to unmodified KTTKS, though both peptides showed rapid degradation in the absence of protease inhibitors [10].

3. Clinical Evidence

Robinson et al. (2005) -- Landmark Double-Blind Trial

The most frequently cited clinical study of Matrixyl was conducted by Robinson et al. and published in the International Journal of Cosmetic Science [5]. This 12-week, double-blind, placebo-controlled, split-face trial enrolled 93 Caucasian female subjects aged 35 to 55. Participants applied a moisturizer containing 3 ppm Pal-KTTKS to one side of the face and a matching vehicle-only moisturizer to the other side.

Key results:

• Pal-KTTKS provided statistically significant reduction in wrinkles and fine lines versus placebo control
• Improvements were confirmed by both quantitative technical analysis (profilometry) and independent expert grader image analysis
• Self-assessment questionnaires showed subjects perceived significant improvements in fine lines and wrinkles
• The peptide was well tolerated with no reported irritation or adverse effects [5]

Sederma Proprietary Clinical Data

Sederma's own clinical testing program generated additional efficacy data, including a 28-day study using optical profilometry to quantify changes in periorbital wrinkles treated with 0.005% palmitoyl pentapeptide-4 cream [9]:

• Fold depth decreased by 18%
• Fold thickness decreased by 37%
• Skin rigidity improved by 21%

A longer-duration study (4 months, double-blinded) with 5 ppm palmitoyl pentapeptide reported substantial improvements in skin roughness, wrinkle volume, and wrinkle depth. Skin biopsies from 6 participants demonstrated increased production and enhanced structural organization of both elastin and collagen IV [9].

Comparison with Retinol

A comparative study evaluated 3 ppm Pal-KTTKS against 700 ppm (0.07%) retinol and found that both treatments produced similar wrinkle-improving effects over the study period [5][9]. The palmitoyl pentapeptide demonstrated notably superior tolerability, with no irritation reported, in contrast to the erythema, peeling, and dryness commonly associated with retinoid use. This finding positioned Matrixyl as a potential alternative for individuals unable to tolerate retinoids [9][21].

Park et al. (2022) -- Wound Healing

In a comparative in vivo study published in ACS Omega, Pourmojib et al. evaluated Matrixyl in both cream and patch formulations for wound healing in a rat model [12]. Animals were divided into seven groups and studied over 21 days. Wound healing improved from 63.5% in the negative control group to up to 81.8% in Matrixyl treatment groups. Both cream and patch formulations containing 1 mg Matrixyl outperformed the positive control (Comfeel hydrocolloid dressing). Patch delivery achieved superior re-epithelialization and collagen production compared to cream [12].

4. The Matrixyl Family

Sederma expanded the Matrixyl brand into a family of related peptide active ingredients, each targeting different aspects of skin aging.

Matrixyl 3000 (Palmitoyl Tripeptide-1 + Palmitoyl Tetrapeptide-7)

Matrixyl 3000 is a dual-peptide complex combining palmitoyl tripeptide-1 (Pal-GHK) and palmitoyl tetrapeptide-7 (Pal-GQPR), designed to simultaneously address two processes of skin aging [4][16]:

Palmitoyl tripeptide-1 is a lipidated derivative of the tripeptide GHK (glycyl-histidyl-lysine), which itself is a naturally occurring matrikine. It activates fibroblast matrix receptors, stimulating synthesis of collagens I, III, and IV, fibronectin, and hyaluronic acid through a mechanism analogous to Matrixyl [16].

Palmitoyl tetrapeptide-7 targets the inflammatory dimension of skin aging (inflammaging) by inhibiting the release of interleukin-6 (IL-6) from keratinocytes. IL-6 is a pro-inflammatory cytokine whose levels increase with age and contribute to chronic degradation of the extracellular matrix and glycation of existing collagen fibers.

The synergistic combination addresses both ECM degradation (via Pal-GHK-mediated matrix synthesis) and chronic low-grade inflammation (via Pal-GQPR-mediated IL-6 suppression).

Matrixyl Synthe'6 (Palmitoyl Tripeptide-38)

Matrixyl Synthe'6, launched by Sederma in 2011, contains palmitoyl tripeptide-38, which stimulates the synthesis of six key structural components of the dermal matrix and dermal-epidermal junction:

1. Collagen I
2. Collagen III
3. Collagen IV
4. Hyaluronic acid
5. Fibronectin
6. Laminin

In vivo testing on 25 volunteers applying 2% Matrixyl Synthe'6 cream twice daily showed a decrease in the surface area occupied by deep crow's feet wrinkles of 28.5% after two months and wrinkle volume reduction on the forehead of up to 100% after two months.

5. Dosing in Research

Matrixyl is notable for being active at extremely low concentrations. Clinical efficacy has been demonstrated at concentrations as low as 3 ppm (0.0003%) of the active Pal-KTTKS peptide, though commercial products vary widely in their actual peptide content. The following reflects doses reported in published research and are not recommendations for human use.

6. Safety and Side Effects

Palmitoyl pentapeptide-4 has an extensively documented safety profile, reflecting its widespread use as a cosmetic ingredient for over two decades.

CIR Safety Assessment (2024)

The Cosmetic Ingredient Review (CIR) Expert Panel assessed the safety of palmitoyl pentapeptide-4 and related pentapeptide ingredients in 2024 [13]. The Panel concluded that these ingredients are safe in cosmetics in the present practices of use and concentration. According to 2023 VCRP survey data, palmitoyl pentapeptide-4 was reported in 239 cosmetic formulations, 223 of which were leave-on products [13].

Dermal Irritation and Sensitization

In guinea pig dermal irritation testing, 0.01% palmitoyl pentapeptide-4 applied daily for 14 consecutive days produced only very slight erythema on one animal on days 12 and 13, with no other reactions [13]. Clinical studies in humans have consistently reported excellent tolerability:

• No irritation, erythema, or sensitization in the Robinson et al. double-blind trial of 93 subjects [5]
• No adverse effects in comparative studies with retinol [9]
• The peptide is well tolerated by all skin types including sensitive, oily, and acne-prone skin [13]

Advantages Over Retinoids

A key safety advantage of Matrixyl relative to retinoids (retinol, tretinoin) is the absence of the irritation commonly associated with retinoid use, which can include erythema, peeling, dryness, and photosensitivity. Palmitoyl pentapeptide-4 does not cause photosensitization and does not require the gradual dose escalation protocols typical of retinoid introduction [5][9][21].

Limitations

No long-term safety studies extending beyond typical cosmetic use durations (12-16 weeks) have been published. Safety data for non-topical routes of administration are not available for Pal-KTTKS. The peptide has not been evaluated for use during pregnancy or lactation.

7. Cosmeceutical Evidence Assessment

Matrixyl occupies a position of moderate evidence within the cosmeceutical landscape. Its evidence base includes:

Strengths:

• Well-characterized molecular target with identified parent sequence (procollagen I C-propeptide) [1]
• Defined mechanism of action through the matrikine signaling pathway [2][4]
• At least one double-blind, placebo-controlled clinical trial with quantitative endpoints [5]
• Demonstrated dose-dependent TGF-beta upregulation supporting the proposed mechanism [6]
• Proven skin penetration of the palmitoylated form through all skin layers [10]
• Favorable safety profile confirmed by CIR Expert Panel review [13]

Limitations:

• Most clinical data originates from manufacturer-sponsored studies [8]
• Relatively few independent peer-reviewed clinical trials [8]
• Active concentrations used in studies (3-5 ppm) may not reflect actual concentrations in many commercial products [8]
• Abu Samah and Heard (2011) noted a surprising absence of standardized in vitro skin penetration data despite widespread commercial use [8]
• No head-to-head comparisons with prescription-grade retinoids (tretinoin) at equivalent anti-aging concentrations [21]
• Evidence level remains below that of tretinoin and L-ascorbic acid, which have larger independent clinical trial databases [7][21]

The overall evidence level for Matrixyl is classified as moderate -- supported by a plausible mechanism, consistent in vitro data, and clinical studies showing statistically significant effects, but limited by the small number of independent confirmatory trials.

8. Regulatory Status

Palmitoyl pentapeptide-4 is classified as a cosmetic ingredient rather than a pharmaceutical drug in all major regulatory jurisdictions. It is listed in the International Nomenclature of Cosmetic Ingredients (INCI) database and is approved for use in cosmetic products in the United States, European Union, and most other markets.

The ingredient has not received FDA approval for any therapeutic indication. The CIR Expert Panel's 2024 safety assessment provides the most current industry regulatory guidance for cosmetic use [13].

9. Pharmacokinetics

9.1 The Palmitoylation Strategy and Skin Penetration

Matrixyl's pharmacokinetic profile is fundamentally shaped by its palmitoyl conjugation. The unmodified KTTKS pentapeptide (MW approximately 563 Da) is highly hydrophilic and, despite its molecular weight falling near the empirical 500 Da cutoff for transdermal absorption, exhibits essentially zero skin penetration due to its unfavorable partition coefficient [3][10]. Palmitoylation addresses this by adding a C16 fatty acid chain to the N-terminus, increasing the total molecular weight to approximately 802 Da -- above the 500 Da rule -- but dramatically improving partitioning into the lipid-rich intercellular spaces of the stratum corneum [3][10].

Lintner and Peschard (2000) demonstrated that palmitoyl conjugation of peptides improved skin penetration by 100- to 1000-fold compared to unmodified hydrophilic peptides, establishing the palmitoylation strategy that would become standard practice in cosmeceutical peptide design [3].

9.2 Skin Layer Distribution

Choi et al. (2014) provided the most detailed penetration data using Franz diffusion cells with hairless mouse skin [10]:

• Unmodified KTTKS: Not detected in any skin layer (stratum corneum, epidermis, or dermis), confirming that the unmodified pentapeptide cannot penetrate the skin barrier despite its relatively small molecular weight
• Pal-KTTKS: Detected in all three skin layers -- 4.2 micrograms per square centimeter in the stratum corneum, 2.8 micrograms per square centimeter in the epidermis, and 0.3 micrograms per square centimeter in the dermis

This distribution profile is critical because Matrixyl's target -- dermal fibroblasts -- resides in the dermis. The detection of Pal-KTTKS in the dermis, even at relatively low concentrations, provides a pharmacokinetic basis for its proposed mechanism of action that is absent for many other cosmeceutical peptides, including argireline [10].

9.3 Dermal Stability and Metabolic Fate

Pal-KTTKS shows superior resistance to proteolytic degradation compared to unmodified KTTKS [10]. In skin homogenate stability studies, both peptides underwent rapid degradation in the absence of protease inhibitors, but Pal-KTTKS retained higher intact peptide levels over time. The palmitoyl chain likely shields the N-terminal lysine from aminopeptidase attack and slows overall enzymatic degradation [10][15].

Upon reaching the dermis, Pal-KTTKS is believed to undergo eventual hydrolysis of the palmitoyl-lysine amide bond by skin esterases and lipases, releasing free KTTKS and palmitic acid. Free KTTKS can then interact with fibroblast surface receptors to initiate matrikine signaling [8][10]. No formal pharmacokinetic parameters (Cmax, AUC, half-life, clearance) have been determined for either Pal-KTTKS or its metabolites, as systemic absorption from topical application has not been detected.

9.4 Formulation-Dependent Delivery

Abu Samah and Heard (2011) noted a surprising absence of standardized in vitro skin penetration data despite Matrixyl's widespread commercial use [8]. The available data suggest that delivery is highly formulation-dependent: vehicle composition, pH, the presence of penetration enhancers, and occlusion all influence the amount of peptide reaching the dermis. Park et al. (2022) demonstrated that patch delivery achieved superior peptide retention and biological effects compared to cream formulation in a wound healing model, suggesting that occlusive delivery enhances Pal-KTTKS penetration [12].

10. Dose-Response Relationships

10.1 In Vitro Collagen Synthesis Dose-Response

Katayama et al. (1993) established the initial dose-response for KTTKS-stimulated ECM production in human dermal fibroblast cultures [1]. KTTKS retained approximately 80% of the parent procollagen propeptide fragment's activity at micromolar concentrations, with stimulation of collagen types I and III and fibronectin following a dose-dependent curve. The minimum effective concentration for detectable collagen stimulation was in the low micromolar range.

Tsai et al. (2007) confirmed dose-dependent TGF-beta upregulation by KTTKS in tendon cell cultures, with higher peptide concentrations producing greater increases in TGF-beta secretion and more sustained stabilization of procollagen mRNA [6]. The dose-response curve for TGF-beta induction was approximately linear over the 1-100 micromolar range tested.

10.2 Clinical Dose-Response

Clinical studies have used a narrow concentration range, limiting formal dose-response assessment:

• 3 ppm Pal-KTTKS (Robinson et al. 2005): Significant wrinkle and fine line reduction versus placebo over 12 weeks in 93 subjects [5]
• 5 ppm Pal-KTTKS (Sederma data): Substantial improvements in fold depth (18% decrease), fold thickness (37% decrease), and skin rigidity (21% improvement) over 28 days [9]
• 0.1-1.0 mg Matrixyl (Park et al. 2022): Wound healing improved from 63.5% to 81.8% versus negative control, with 1 mg showing greater effects than 0.1 mg [12]

The remarkable finding that clinical efficacy is observed at just 3-5 ppm (0.0003-0.0005%) of active peptide suggests either extreme biological potency of the matrikine signaling cascade, or that even minimal dermal penetration delivers sufficient peptide to trigger a meaningful fibroblast response. A formal dose-escalation study comparing concentrations from 1 to 50 ppm has not been published.

10.3 Duration-Dependent Effects

Available data suggest progressive improvement with continued use:

• 4 weeks: Measurable reductions in wrinkle depth and roughness parameters (Sederma data) [9]
• 12 weeks: Significant improvements confirmed by both profilometry and expert grading (Robinson et al.) [5]
• 16 weeks: Skin biopsies showing increased elastin and collagen IV organization (Sederma data) [9]

Unlike retinoids, Matrixyl does not exhibit an initial "worsening phase" and improvements appear to begin within the first weeks of use, though the full magnitude of effect develops over months of consistent application.

11. Comparative Effectiveness

11.1 Matrixyl versus Retinoids

The comparison with retinoids is the most clinically relevant for Matrixyl positioning:

Retinol (0.07%): A Sederma-sponsored comparative study found that 3 ppm Pal-KTTKS and 700 ppm (0.07%) retinol produced similar wrinkle-improving effects over the study duration [5][9]. This is a significant finding given that retinol is the most widely validated over-the-counter anti-aging ingredient. However, the comparison has limitations: 0.07% retinol is at the lower end of effective retinol concentrations, and no comparison with higher-concentration retinol (0.5-1%) or prescription tretinoin (0.025-0.1%) has been published.

Tretinoin (prescription retinoid): No head-to-head comparison exists. Tretinoin has Level I evidence from large, long-duration RCTs demonstrating collagen synthesis stimulation, epidermal thickening, and wrinkle reduction. Matrixyl's evidence base is smaller and more manufacturer-dependent. However, tretinoin causes significant irritation (retinoid dermatitis) in many patients, whereas Matrixyl is universally well tolerated [5][9][21].

Clinical niche: Matrixyl is best positioned as an alternative for retinoid-intolerant patients, a complement to retinoid therapy (targeting ECM synthesis through a different pathway), or a first-line anti-aging peptide for patients with sensitive or reactive skin [9][21].

11.2 Matrixyl versus GHK-Cu (Copper Tripeptide-1)

Both Matrixyl and GHK-Cu stimulate collagen synthesis in dermal fibroblasts, but through distinct mechanisms:

• Matrixyl: Acts as a matrikine signal peptide mimicking procollagen degradation fragments, triggering compensatory ECM synthesis via TGF-beta upregulation [1][6]
• GHK-Cu: Delivers bioavailable copper to copper-dependent enzymes (lysyl oxidase, SOD) and modulates expression of approximately 4,048 genes involved in tissue remodeling, antioxidant defense, and anti-inflammatory signaling [16]

GHK-Cu has a broader biological profile (wound healing, anti-inflammatory, antioxidant, hair growth) and a longer research history, but Matrixyl has more controlled clinical trial data specifically for wrinkle reduction. The Leyden et al. (2002) trial found GHK-Cu cream improved skin laxity and fine lines versus both placebo and vitamin C cream, but no direct Matrixyl-vs-GHK-Cu comparison exists. The two peptides target complementary pathways and are frequently combined in multi-peptide formulations [16].

11.3 Matrixyl versus Vitamin C (L-Ascorbic Acid)

L-ascorbic acid (10-20%) is the most studied topical antioxidant for anti-aging:

• Mechanism: Vitamin C serves as a cofactor for prolyl and lysyl hydroxylases essential for collagen cross-linking, provides photoprotection via free radical scavenging, and inhibits melanogenesis. Matrixyl stimulates new collagen transcription rather than supporting post-translational collagen processing [21].
• Evidence level: Vitamin C has a larger independent evidence base, though its efficacy is heavily dependent on formulation stability (pH under 3.5, anhydrous or stabilized forms required) [21].
• Combination rationale: Matrixyl and vitamin C target different steps in the collagen synthesis pathway (transcription/signaling vs. post-translational modification), providing a strong rationale for combination use. No adverse interactions have been reported.

11.4 Matrixyl versus Argireline

The 2023 Wisesa et al. double-blind RCT directly compared palmitoyl pentapeptide-4 and acetylhexapeptide-3 for crow's feet in 21 Indonesian women over 8 weeks [5]. Matrixyl outperformed argireline in most measured skin parameters, consistent with its better-characterized mechanism and confirmed dermal penetration. The two peptides target fundamentally different biological processes (ECM remodeling vs. SNARE complex modulation) and are commonly combined in commercial products.

12. Enhanced Safety Profile

12.1 Long-Term Safety Considerations

Palmitoyl pentapeptide-4 has been in continuous commercial use since 2000, providing over 25 years of real-world safety data. The CIR Expert Panel's 2024 comprehensive safety assessment concluded that the ingredient is safe in cosmetics in present practices of use and concentration [13]. No post-market safety signals, adverse event clusters, or regulatory actions have been reported in any jurisdiction.

12.2 Systemic Exposure Assessment

Because Pal-KTTKS is applied topically at extremely low concentrations (3-5 ppm active peptide) and undergoes proteolytic degradation in the skin, systemic exposure is expected to be negligible. The CIR panel noted that even if the peptide were fully absorbed, the resulting systemic dose would be orders of magnitude below any level of biological concern [13]. No systemic adverse effects have been reported in any published study.

12.3 Dermatological Safety

In guinea pig dermal irritation testing, daily application of 0.01% palmitoyl pentapeptide-4 for 14 consecutive days produced only very slight erythema on one animal on days 12 and 13 [13]. Human clinical studies consistently report excellent tolerability:

• No irritation, erythema, peeling, or sensitization in any published trial [5][9][13]
• No phototoxicity or photosensitivity [13]
• Safe for use on all skin types including sensitive, rosacea-prone, oily, and acne-prone skin [13]
• No contraindication for use around the eyes, which is relevant given that periorbital wrinkles are the primary clinical target [5]

12.4 Special Populations

Pregnancy and lactation: No specific studies have evaluated safety during pregnancy or breastfeeding. Given the negligible systemic absorption from topical application at cosmetic concentrations, risk is expected to be extremely low, but no formal guidance has been issued.

Pediatric use: Not applicable; Matrixyl is formulated for anti-aging applications in adult skin.

Concurrent use with procedures: No published data address use immediately following chemical peels, laser treatments, or microneedling. Standard practice is to avoid active ingredients on disrupted skin barriers until re-epithelialization is complete.

12.5 Ingredient Interactions

Palmitoyl pentapeptide-4 has been formulated with a wide range of cosmetic actives without reported adverse interactions, including hyaluronic acid, niacinamide, retinol, vitamin C, alpha-hydroxy acids, and other peptides (Matrixyl 3000, argireline, copper peptides). The peptide's stability is optimal at pH 5.0-7.0 and may be compromised in highly acidic formulations (pH under 3.5) [13][20].

13. Related Peptides

See also: GHK-Cu, Argireline, Collagen Peptides

14. References

1. [1] Katayama K, Armendariz-Borunda J, Raghow R, et al. (1993). A pentapeptide from type I procollagen promotes extracellular matrix production. Journal of Biological Chemistry. DOI PubMed
2. [2] Maquart FX, Pira S, Gillery P, et al. (1999). Regulation of cell activity by the extracellular matrix: the concept of matrikines. Journal de la Societe de Biologie. PubMed
3. [3] Lintner K, Peschard O (2000). Biologically active peptides: from a laboratory bench curiosity to a functional skin care product. International Journal of Cosmetic Science. DOI
4. [4] Maquart FX, Bellon G, Pira S, et al. (2004). An introduction to matrikines: extracellular matrix-derived peptides which regulate cell activity -- implication in tumor invasion. Critical Reviews in Oncology/Hematology. DOI PubMed
5. [5] Robinson LR, Fitzgerald NC, Piecber DG, et al. (2005). Topical palmitoyl pentapeptide provides improvement in photoaged human facial skin. International Journal of Cosmetic Science. DOI PubMed
6. [6] Tsai WC, Hsu CC, Hung LK, et al. (2007). The pentapeptide KTTKS promoting the expressions of type I collagen and transforming growth factor-beta of tendon cells. Journal of Orthopaedic Research. DOI PubMed
7. [7] Lupo MP, Cole AL (2007). Cosmeceutical peptides. Dermatologic Therapy. DOI PubMed
8. [8] Abu Samah NH, Heard CM (2011). Topically applied KTTKS: a review. International Journal of Cosmetic Science. DOI PubMed
9. [9] Schagen SK (2017). Topical peptide treatments with effective anti-aging results. Cosmetics. DOI
10. [10] Choi YL, Park EJ, Kim E, et al. (2014). Dermal stability and in vitro skin permeation of collagen pentapeptides (KTTKS and palmitoyl-KTTKS). Biomolecules and Therapeutics. DOI PubMed
11. [11] Park HY, An SH (2017). Effect of palmitoyl-pentapeptide (Pal-KTTKS) on wound contractile process in relation with connective tissue growth factor and alpha-smooth muscle actin expression. International Wound Journal. DOI
12. [12] Pourmojib M, Amoabediny G, Sheikhpour M, et al. (2022). Matrixyl patch vs Matrixyl cream: a comparative in vivo investigation of Matrixyl (MTI) effect on wound healing. ACS Omega. DOI PubMed
13. [13] Cosmetic Ingredient Review Expert Panel (2024). Safety assessment of myristoyl pentapeptide-4, palmitoyl pentapeptide-4, and pentapeptide-4 as used in cosmetics. International Journal of Toxicology.
14. [14] Ferreira MS, Magalhaes MC, Sousa-Lobo JM, Almeida IF (2020). Trending anti-aging peptides. Cosmetics. DOI
15. [15] Errante F, Ledwoń P, Bhatt TK, et al. (2019). The effects of a novel series of KTTKS analogues on cytotoxicity and proteolytic activity. Molecules. DOI PubMed
16. [16] Pickart L, Vasquez-Soltero JM, Margolina A (2015). GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration. BioMed Research International. DOI PubMed
17. [17] Rigano L, Lionetti N (2016). Nanobiomaterials in galenic formulations and cosmetics. Nanobiomaterials in Galenic Formulations and Cosmetics, Elsevier. DOI
18. [18] Hussain M, Goldberg DJ (2007). Topical manganese peptide in the treatment of photodamaged skin. Journal of Cosmetic and Laser Therapy. DOI
19. [19] Pai VV, Bhandari P, Shukla P (2017). Topical peptides as cosmeceuticals. Indian Journal of Dermatology, Venereology and Leprology. DOI PubMed
20. [20] Deprez S, Bhatt TK, Bhatt NP, et al. (2025). Bioactive peptides in cosmetic formulations: review of current in vitro and ex vivo evidence. Peptides. DOI
21. [21] Gorouhi F, Maibach HI (2009). Role of topical peptides in preventing or treating aged skin. International Journal of Cosmetic Science. DOI PubMed
22. [22] Fields K, Falla TJ, Rodan K, Bush L (2009). Bioactive peptides: signaling the future. Journal of Cosmetic Dermatology. DOI PubMed
23. [23] Song J, Kim D, Lee S, et al. (2025). Peptides: emerging candidates for the prevention and treatment of skin senescence. International Journal of Molecular Sciences. DOI PubMed